Bicalutamide ('Casodex') 150mg in addition to standard care in patients with nonmetastatic prostate cancer: Updated results from a randomised double-blind phase III study (median follow-up 5.1y) in the early prostate cancer programme

M. Wirth*, C. Tyrrell, K. Delaere, M. Sánchez-Chapado, J. Ramon, D. M.A. Wallace, J. Hetherington, F. Pina, C. Heyns, T. Borchers, T. Morris, J. Armstrong

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

23 Scopus citations

Fingerprint

Dive into the research topics of 'Bicalutamide ('Casodex') 150mg in addition to standard care in patients with nonmetastatic prostate cancer: Updated results from a randomised double-blind phase III study (median follow-up 5.1y) in the early prostate cancer programme'. Together they form a unique fingerprint.

Medicine & Life Sciences